Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer J Tie et al, JAMA Oncology, October 17, 2019

Hot Topics of the Day|PHGKB




Last Posted: Oct 18, 2019

---

• Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
  J Tie et al, JAMA Oncology, October 17, 2019
• Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience.
  Vitiello Pietro Paolo et al. Cancers 2019 Oct 11(10)
• DNA Methylation Markers for Pan-Cancer Prediction by Deep Learning.
  Liu Biao et al. Genes 2019 Oct 10(10)
• Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy.
  Li Gerald et al. Journal of gastrointestinal oncology 2019 Oct 10(5) 831-840
• Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy.
  Hsieh Jason Chia-Hsun et al. Head & neck 2019 Oct 41 Suppl 119-45
• Liquid biopsy: one cell at a time
  SB Lim et al, NPJ Precision Oncology, October 2019
• Circulating tumor DNA and their added value in molecular oncology.
  Leers Math P G et al. Clinical chemistry and laboratory medicine 2019 Sep
• Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies.
  Cimadamore Alessia et al. Expert review of molecular diagnostics 2019 Sep 1-10
• The current status of the clinical utility of liquid biopsies in cancer.
  Snow Anson et al. Expert review of molecular diagnostics 2019 Sep 1-11
• Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.
  Parikh Aparna R et al. Nature medicine 2019 Sep (9) 1415-1421

more